SANUWAVE Health Reports Q1 2026 Results: Net Loss Significantly Reduced, Reiterates Full-Year Guidance

summarizeSummary

SANUWAVE Health announced Q1 2026 financial results, highlighting a substantial reduction in net loss and positive operational trends in consumables, alongside reiterated full-year revenue guidance.

check_boxKey Events

• Q1 2026 Financial Results

  Revenue for Q1 2026 was $9.6 million, a 3.1% increase from $9.3 million in Q1 2025. Gross margin decreased slightly to 77.3% from 79.0%.

• Significant Net Loss Reduction

  Net loss for Q1 2026 was $1.4 million, a substantial improvement from a $6.1 million net loss in Q1 2025, primarily due to the absence of a $4.9 million non-cash derivative liability loss from the prior year.

• Operational Strength in Consumables

  Ultramist® consumables revenue increased by 15.0% year-over-year to $6.7 million, and unit volumes for consumables set a new all-time record, indicating increased utilization.

• CEO Optimism on Market Recovery

  CEO Morgan Frank noted that a market recovery appears to have begun in February, with increasing optimism and a robust pipeline for the remainder of 2026.

auto_awesomeAnalysis

SANUWAVE Health reported a significant reduction in its net loss for Q1 2026, improving to $1.4 million from $6.1 million in the prior year, largely due to the absence of a non-cash derivative liability loss. While operating income swung to a loss, the company achieved modest revenue growth and saw a 15% increase in Ultramist® consumables revenue, with unit volumes setting a new all-time record. The CEO expressed optimism about a market recovery beginning in February and reiterated positive full-year revenue guidance, which is a crucial signal for investors, especially with the stock trading near its 52-week low.